Cabaletta Bio (CABA) Capital Expenditures (2019 - 2025)
Cabaletta Bio (CABA) posted quarterly Capital Expenditures of -$43000.0 for Q3 2025, down 117.0% year-over-year from $253000.0 in Q3 2024, and up 94.2% quarter-over-quarter from -$742000.0 in Q2 2025.
Powered by 
Analysis
Cabaletta Bio (CABA) Capital Expenditures (2019 - 2025) Analysis & Trends
Cabaletta Bio's Capital Expenditures history runs 7 years deep, the most recent figure standing at -$43000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures fell 117.0% year-over-year to -$43000.0; the TTM figure through Sep 2025 stood at $376000.0 (down 81.52% YoY), while the FY2024 annual figure was $2.2 million, up 214.96% from the prior year.
- Capital Expenditures for Q3 2025 stood at -$43000.0, up from -$742000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.7 million in Q3 2022, with the low at -$2.1 million in Q4 2022.
- The 5-year median for Capital Expenditures is $261000.0 (2022), against an average of $226611.1.
- The sharpest annual moves came in 2021 and 2024: Capital Expenditures tumbled 374.07% in 2021, then surged 3900.0% in 2024.
- Cabaletta Bio's Capital Expenditures stood at $1.1 million in 2021, then slumped by 296.06% to -$2.1 million in 2022, then soared by 109.36% to $200000.0 in 2023, then soared by 88.0% to $376000.0 in 2024, then slumped by 111.44% to -$43000.0 in 2025.
- Business Quant data shows CABA's Capital Expenditures at -$43000.0 in Q3 2025, -$742000.0 in Q2 2025, and $785000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 205,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 785,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 253,000.00 |
| Jun 30, 2024 | 770,000.00 |
| Mar 31, 2024 | 812,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 57,000.00 |
| Mar 31, 2023 | 380,000.00 |
| Dec 31, 2022 | 316,000.00 |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 898,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 151,000.00 |
| Sep 30, 2021 | 495,000.00 |
| Jun 30, 2021 | 144,000.00 |
| Mar 31, 2021 | 376,000.00 |